Current Report · Items 8.01 · 8-K
Kyntra Bio, Inc.
KYNBNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On June 2, 2026, Kyntra Bio, Inc. (the “Company”) received $4.0 million from AstraZeneca Treasury Limited (“AstraZeneca”). This amount is in full satisfaction of the second and final holdback set forth in the share purchase agreement entered into between the Company and AstraZeneca on February 20, 2025 (the “Share Purchase Agreement”).…
Filed Jun 9, 2026Accepted Jun 9, 2026, 5:04 PM EDTCIK 921299Accession 0001193125-26-264000
Company context
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
Current securities
Disclosure sections
Items 8.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On June 2, 2026, Kyntra Bio, Inc. (the “Company”) received $4.0 million from AstraZeneca Treasury Limited (“AstraZeneca”). This amount is in full satisfaction of the second and final holdback set forth in the share purchase agreement entered into between the Company and AstraZeneca on February 20, 2025 (the “Share Purchase Agreement”).
On August 29, 2025, the Company closed the sale of its China operations through FibroGen International (Hong Kong) Ltd. to AstraZeneca pursuant to the Share Purchase Agreement for a total consideration of approximately $220 million comprised of $85 million in enterprise value and approximately $135 million in net cash held in China. The total consideration included $210 million paid at closing, and $10.0 million payable by AstraZeneca after closing and subject to the following holdbacks and conditions: (i) a $6.0 million holdback to offset final net cash adjustments, following a customary adjustment process, and (ii) a $4.0 million holdback to satisfy any indemnity claims. In November 2025, the Company received the first holdback of $6.0 million, plus $0.4 million that was an additional payment following the final net cash adjustments after closing. As no indemnity claims were made, the Company has now received the entire $4.0 million holdback, which completes the collection of all owed amounts under the Share Purchase Agreement with AstraZeneca.